1-5 of 5
Vanitha Ramakrishnan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TriTACs, a Novel Class of T-Cell–Engaging Protein Constructs Designed for the Treatment of Solid Tumors

Richard J. Austin, Bryan D. Lemon, Wade H. Aaron, Manasi Barath, Patricia A. Culp, Robert B. DuBridge, Luke B. Evnin, Adrie Jones, Anand Panchal, Purbasa Patnaik, Vanitha Ramakrishnan, Sony S. Rocha, Pui Seto, Kenneth Sexton, Kathryn L. Strobel, Russell Wall, Stephen Yu, Timothy Z. Yu, Che-Leung Law, Patrick A. Baeuerle, Holger Wesche
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (1): 109–120.
https://doi.org/10.1158/1535-7163.MCT-20-0061
Published: 05 January 2021
View articletitled, TriTACs, a Novel Class of T-Cell–Engaging Protein Constructs Designed for the Treatment of Solid Tumors
Open the PDF for TriTACs, a Novel Class of T-Cell–Engaging Protein Constructs Designed for the Treatment of Solid Tumors in another window
Includes: Supplementary data
Journal Articles

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Dongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, Randall Dere, MaryAnn Go, Jeffrey Lau, Bing Zheng, Kristi Elkins, Dimitry Danilenko, Katherine R. Kozak, Pamela Chan, Josefa Chuh, Xiaoyan Shi, Denise Nazzal, Franklin Fuh, Jacqueline McBride, Vanitha Ramakrishnan, Ruth de Tute, Andy Rawstron, Andrew S. Jack, Rong Deng, Yu-Waye Chu, David Dornan, Marna Williams, William Ho, Allen Ebens, Saileta Prabhu, Andrew G. Polson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (7): 1255–1265.
https://doi.org/10.1158/1535-7163.MCT-12-1173
Published: 07 July 2013
View articletitled, DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Open the PDF for DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract A135: T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner.

Kaushiki Mahapatra, Walter Darbonne, Daniela Bumbaca, Ben Shen, Xiaoyan Du, Jack Tibbitts, Steve Olsen, Mark Sliwkowski, Sandhya Girish, Dylan Hartley, Donna Dambach, Vanitha Ramakrishnan, Hirdesh Uppal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A135.
https://doi.org/10.1158/1535-7163.TARG-11-A135
Published: 12 November 2011
View articletitled, Abstract A135: T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner.
Journal Articles

Abstract B154: A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues.

Yibing Yan, Marie-Claire Wagle, Elizabeth Punnoose, Luna Musib, Nageshwar Budha, Michelle Nannini, Kui Lin, Bianca M. Liederer, Sumati Murli, Vanitha Ramakrishnan, Premal Patel, Andrs Cervantes, Josep Tabernero
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B154.
https://doi.org/10.1158/1535-7163.TARG-11-B154
Published: 12 November 2011
View articletitled, Abstract B154: A first-in-human trial of GDC-0068: A novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of the Akt pathway in surrogate and tumor tissues.
Journal Articles

Preclinical validation of anti-TMEFF2-auristatin E–conjugated antibodies in the treatment of prostate cancer

Daniel E.H. Afar, Vinay Bhaskar, Eric Ibsen, Danna Breinberg, Susan M. Henshall, James G. Kench, Marija Drobnjak, Rick Powers, Melanie Wong, Ferdinand Evangelista, Chris O'Hara, David Powers, Robert B. DuBridge, Ingrid Caras, Ruth Winter, Terri Anderson, Nanette Solvason, Phillip D. Stricker, Carlos Cordon-Cardo, Howard I. Scher, John J. Grygiel, Robert L. Sutherland, Richard Murray, Vanitha Ramakrishnan, Debbie A. Law
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (8): 921–932.
https://doi.org/10.1158/1535-7163.921.3.8
Published: 06 August 2004
View articletitled, Preclinical validation of anti-TMEFF2-auristatin E–conjugated antibodies in the treatment of prostate cancer
Open the PDF for Preclinical validation of anti-TMEFF2-auristatin E–conjugated antibodies in the treatment of prostate cancer in another window